Discounted Cash Flow
Adma Biologics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $10.5m | $-19.5m | $-18.3m | -185.5% | $-1.61 |
| 2017 | $15.6m (48.5%) | $-43.8m (-124.2%) | $-39.9m (-117.8%) | -280.2% (-51.0%) | $-1.91 (-18.6%) |
| 2018 | $17.0m (8.8%) | $-65.7m (-50.2%) | $-64.8m (-62.1%) | -387.1% (-38.1%) | $-1.45 (24.1%) |
| 2019 | $29.3m (72.8%) | $-48.3m (26.6%) | $-80.0m (-23.5%) | -164.5% (57.5%) | $-0.89 (38.6%) |
| 2020 | $42.2m (43.9%) | $-75.7m (-56.9%) | $-114.7m (-43.4%) | -179.4% (-9.1%) | $-0.88 (1.1%) |
| 2021 | $80.9m (91.7%) | $-71.6m (5.4%) | $-125.9m (-9.7%) | -88.5% (50.7%) | $-0.51 (42.0%) |
| 2022 | $154.1m (90.4%) | $-65.9m (8.0%) | $-73.4m (41.7%) | -42.8% (51.7%) | $-0.33 (35.3%) |
| 2023 | $258.2m (67.6%) | $-28.2m (57.2%) | $4.0m (105.5%) | -10.9% (74.4%) | $-0.13 (60.6%) |
| 2024 | $426.5m (65.2%) | $197.7m (800.0%) | $110.4m (2641.3%) | 46.4% (523.8%) | $0.85 (753.8%) |
| 2025 | $510.2m (19.6%) | $146.9m (-25.7%) | $27.8m (-74.8%) | 28.8% (-37.9%) | $0.62 (-27.1%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.